Business Description
BioVie Inc
NAICS : 325412
SIC : 2834
ISIN : US09074F5044
Share Class Description:
BIVI: Ordinary Shares - Class ATotal Employee Number:
13Description
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 32.64 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 72.2 | |||||
3-Year EPS without NRI Growth Rate | 72.7 | |||||
3-Year FCF Growth Rate | 72.3 | |||||
3-Year Book Growth Rate | -68.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 40.78 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 35.89 | |||||
9-Day RSI | 48.75 | |||||
14-Day RSI | 51.84 | |||||
3-1 Month Momentum % | -32.52 | |||||
6-1 Month Momentum % | -19.71 | |||||
12-1 Month Momentum % | -42.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.59 | |||||
Quick Ratio | 3.59 | |||||
Cash Ratio | 2.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -174.7 | |||||
Shareholder Yield % | -58.91 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -123.9 | |||||
ROA % | -107.52 | |||||
ROIC % | -1442.37 | |||||
3-Year ROIIC % | -213.3 | |||||
ROC (Joel Greenblatt) % | -7308.15 | |||||
ROCE % | -122.22 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.44 | |||||
Price-to-Tangible-Book | 1.48 | |||||
EV-to-EBIT | -0.35 | |||||
EV-to-Forward-EBIT | -7.13 | |||||
EV-to-EBITDA | -0.36 | |||||
EV-to-FCF | -0.41 | |||||
| Price-to-Net-Current-Asset-Value | 1.53 | |||||
| Price-to-Net-Cash | 2.96 | |||||
Earnings Yield (Greenblatt) % | -285.71 | |||||
FCF Yield % | -115.16 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BIVI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioVie Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.15 | ||
| Beta | -0.8882 | ||
| 3-Year Sharpe Ratio | -0.63 | ||
| 3-Year Sortino Ratio | -0.89 | ||
| Volatility % | 82.71 | ||
| 14-Day RSI | 51.84 | ||
| 14-Day ATR ($) | 0.305711 | ||
| 20-Day SMA ($) | 1.87497 | ||
| 12-1 Month Momentum % | -42.41 | ||
| 52-Week Range ($) | 0.82 - 3.79 | ||
| Shares Outstanding (Mil) | 8.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioVie Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioVie Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2027-02-05 | In 147 days | ||
| General meeting for 2026 | 2026-11-10 11:00 | In 61 days | ||
| First quarter earnings results for 2027 | 2026-11-10 | In 60 days | ||
| Annual report for 2026 | 2026-08-14 | 1.56 (-5.45%) | ||
| Third quarter earnings results for 2026 | 2026-05-11 | 1.47 (-4.55%) | ||
| Second quarter earnings results for 2026 | 2026-02-06 | 1.06 (-7.02%) | ||
| General meeting for 2025 | 2025-11-10 11:00 | 1.48 (-0.67%) | ||
| First quarter earnings results for 2026 | 2025-11-10 | 1.48 (-0.67%) | ||
| Annual report for 2025 | 2025-08-15 | 1.66 (-5.14%) | ||
| 0.1:1 Stock Split | 2025-07-07 | 9.60 (+1.05%) |
Show
Entries
BioVie Inc Frequently Asked Questions
What is BioVie Inc(BIVI)'s stock price today?
The current price of BIVI is $1.96. The 52 week high of BIVI is $3.79 and 52 week low is $0.82.
When is next earnings date of BioVie Inc(BIVI)?
The next earnings date of BioVie Inc(BIVI) is 2026-11-10 Est..
Does BioVie Inc(BIVI) pay dividends? If so, how much?
BioVie Inc(BIVI) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers